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Abstract
Background: Risk stratification based on cytogenetics of acute myeloid leukemia (AML) remains imprecise. The
introduction of novel genetic and epigenetic markers has helped to close this gap and increased the specificity
of risk stratification, although most studies have been conducted in specific AML subpopulations. In order to
overcome this limitation, we used a genome-wide approach in multiple AML populations to develop a robust
prediction model for AML survival.
Methods: We conducted a genome-wide expression analysis of two data sets from AML patients enrolled into the
AMLCG-1999 trial and from the Tumor Cancer Genome Atlas (TCGA) to develop a prognostic score to refine current
risk classification and performed a validation on two data sets of the National Taiwan University Hospital (NTUH)
and an independent AMLCG cohort.
Results: In our training set, using a stringent multi-step approach, we identified a small three-gene prognostic
scoring system, named Tri-AML score (TriAS) which highly correlated with overall survival (OS). Multivariate analysis
revealed TriAS to be an independent prognostic factor in all tested training and additional validation sets, even
including age, current cytogenetic-based risk stratification, and three other recently developed expression-based
scoring models for AML.
Conclusions: The Tri-AML score allows robust and clinically practical risk stratification for the outcome of AML
patients. TriAS substantially refined current ELN risk stratification assigning 44.5 % of the patients into a different
risk category.
Abbreviations: AML, Acute myeloid leukemia; TCGA, Tumor Cancer Genome Atlas; NTUH, National Taiwan
University Hospital; TriAS, Tri-AML score; CN-AML, Cytogenetically normal AML; FDR, False discovery rate;
GO, Gene ontology; RFS, Relapse-free survival; pts, Points; OS, Overall survival; ELN, European LeukemiaNet;
HCC, Hepatocellular carcinoma; ALL, Acute lymphoblastic leukemia
Key points
 TriAS improves risk stratification in AML
 TriAS is robust in multivariate analysis compared to
established risk factors
Background
The biological heterogeneity of acute myeloid leukemia
(AML) in combination with patient-related risk factors
such as age or co-morbidities result in a wide range of
clinical outcomes making it a continuous challenge for
clinicians to assess individual patients’ risk. Currently
applied risk-prognostication models mainly rely on a
combination of pre-treatment karyotype and molecular
mutations. Recent improvements have been made in prog-
nostication, e.g., by adding individual molecular markers
to conventional cytogenetics—particularly in patients with
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normal karyotype AML. The large variability of outcomes
within these individual risk groups suggests that more
sophisticated approaches including epigenetics [1, 2],
microRNA [3], or scoring models based on individual
genes [4, 5] are required to provide a more personalized
risk assessment. While these studies represent a great leap
forward, several of these studies contain certain limita-
tions, often analyzing only a specific AML subset [3, 5],
such as cytogenetically normal AML (CN-AML), which
only counts for 40 to 50 % of adult and 25 % of pediatric
AML patients [6, 7].
In this regard, improved risk stratification is still an
unmet clinical need also in elderly AML patients with still
poor long-term overall survival (OS) [8]. In order to over-
come some of these limitations, we used an unbiased
genome-wide approach to identify reliable genetic markers




In total, four data sets were used in this study. Two inde-
pendent data sets comprising of total 242 patients served
as training sets, including 163 patients from the TCGA
portal investigated using RNAseq technology [9] and 79
patients from which 62 were enrolled in the German
AML Cooperative Group (AMLCG) 1999 trial [10], while
17 had received therapy outside of the trial [4] using the
Affymetrix 133 Plus 2.0 platform (GSE12417-GPL570).
Two additional independent validation sets were derived
from either 227 patients at the National Taiwan University
Hospital (NTUH) [11] (validation set 1) using the Illumina
HumanHT-12 v4 Expression BeadChip platform as well as
a second set derived from additional 163 patients enrolled
in the AMLCG 1999 trial (GSE12417-GPL96A and B,
validation set 2) using the Affymetrix 133 Plus 2.0 plat-
form. Clinical characteristics and survival endpoints were
used as described in the individual gene expression data
sets [4, 9, 11]. Cytogenetic risk groups were available for
all data sets, even though the AMLCG data set included
CN-AML patients only.
Identification of prognostic genes
We used a multi-step approach in order to identify the
most reliable combination of expression-based markers
(Fig. 1). In order to facilitate generation and validation of a
score, only transcripts were included in the analysis where
the corresponding gene was available in all four data sets.
First, univariate Cox regression analysis using the dicho-
tomized expression (higher or lower compared to the
median of the corresponding data set) was conducted to
identify all genes with significant impact on OS in the
training sets (TCGA and GSE570). Next, age was included
as a confounding factor into a multivariate Cox regression
model of each training subset. Selection of those genes
with significant impact on OS in uni- and multivariate ana-
lysis including age in both subsets of the training set with
the same effect direction and expression of the transcripts
in all patient samples led to a candidate list of 30 genes.
Development of expression-based scoring models
In order to systematically evaluate the prediction ability
in the combined training set (TCGA + GSE570) while
reducing the number of genes in our model, we calculated
each best predicting combination of n = 30, n = 29… down
to n = 1 genes using multivariate Cox regression analysis
keeping age >65 years and the cytogenetic risk group
within the model. The model with the highest likelihood
score was identified using the branch-and-bound algo-
rithm of Furnival and Wilson as included in the SAS
software package version 9.3.
An individual score was then created for each n-gene-
combination: For each of the n-genes included in the
score, 1 point was added if expression of the gene was
above the median expression of the data set in case of
genes with a hazard ratio >1 in the multivariate n-gene-
model, whereas 1 point was subtracted in case of a hazard
ratio <1 in the multivariate n-gene-model.
Gene ontology studies
Gene ontology studies were analyzed using the software
platform Cytoscape (Version 3.2.1) [12] and the plugin
BiNGO (Version 2.4.4) [13]. Testing for significant path-
way enrichment in BiNGO was performed using hypergeo-
metric distribution testing and multiple testing correction
by Benjamini & Hochberg False Discovery Rate (FDR) with
a significance cutoff value of p = 0.05.
Computing previously published AML scores (Marcucci
et al., Chuang et al., Li et al.)
For each data set, three recently published expression-
based AML scores have been additionally calculated as
previously described: the dichotomized Marcucci score [5],
the continuous Chuang score[11], and the dichotomized Li
score [14].
Statistical analysis
Gene expression data of each patient was dichotomized
based either on a higher (GeneHI) or lower (GeneLOW)
expression value compared to the median of the cohort of
the individual data set as a cutoff. For the identification of
prognostic genes, univariate Cox regression analysis of
overall survival was performed for each single gene using
the dichotomized expression of each gene. The median
expression for each gene of each microarray data set
served as the cutoff between high and low expression.
Additionally, multivariate Cox regression was performed
including the dichotomized expression and age.
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Fig. 1 Genome-wide approach to identify a robust prognostic clinical score in AML patients. The schematic overview how to identify a robust
AML scoring model using four different expression data sets from TCGA, NTUH, and two independent data sets of the AMLCG-1999 trial
(GSE12417-GPL96 and GSE12417-GPL570) is shown. Statistical analysis was conducted either by uni- or multivariate Cox regression analysis
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Multivariate Cox regression analysis including several
competing risk factors was performed to estimate hazard
ratios and 95 % confidence intervals of our scores in
different data sets. Categorized scores were additionally
plotted using the Kaplan-Meier method. All statistical
tests were two-sided and performed using SAS 9.3 (SAS
Institute Inc., Cary, NC, USA). For all tests, the level of
significance was p < 0.05.
Results
Using a genome-wide approach to identify robust prog-
nostic markers in AML
In order to identify the most reliable genes for a prediction
model, we analyzed 15.939 individual genes and 31.479
sequences available in all four data set (Fig. 1). We found
2.080 genes of the TCGA and 2.001 sequences in 1.752
genes of the GSE12417-GPL570 data set with significant
impact on OS using univariate Cox regression analysis.
When we included age, one of the strongest predictors of
AML survival [15] as a confounding factor, 1.090 genes of
the TCGA and 1.374 sequences in 1.231 genes of the
GSE570 data set remained significant using multivariate
analysis. Of these, 30 genes showed significant impact
on OS with the same effect direction in univariate and
multivariate analysis in both subsets of the training set
(Additional file 1: Table S1).
To assess the functional relevance of these genes, we
conducted gene ontology (GO) analysis which revealed
significant enrichment in pathways related to cell stress,
apoptosis, tyrosine kinase signaling, endocytosis, and cell
cycle (Additional file 1: Table S2).
Computing a prognostic weighted three-gene expression
score led to the Tri-AML score
Several studies have already developed large-gene signa-
tures ranging from 7- to 86-gene prognostic signatures or
weighted scoring models in AML [3–5, 14]. However,
such multi-gene signatures remain difficult to implement
into routine clinical application, as we even considered a
30-gene signature less practical for routine use.
To find an appropriately predictive expression signature,
while using the lowest number of genes, we first merged
both training subsets into one combined training set
including 242 patients (Fig. 1). We then calculated all best
predicting n-out-of-30-gene-scores comprising n = 1, up
to all of our 30 candidate genes. While the number of
possible n-out-of-30-gene-scores dramatically increased up
to 15 genes included (Additional file 1: Figure S1a), the
predictive value of the scores as measured by the multiva-
riate significance level in the combined training set reached
a plateau after eight genes (Additional file 1: Figure S1b).
For further routine use, we propose a 3-gene-combination
to be most appropriate including a reasonable low number
of genes still preserving very high prediction ability. The best
predicting 3-gene-score in our training set included the
genes, C-X-C chemokine receptor type 6 (CXCR6), family
with sequence similarity 124B (FAM124B), and adenylyl
cyclase-associated protein 1 (CAP1) (Fig. 1). While a higher
gene expression of CAP1 and FAM124B was associated with
adverse survival, a higher expression of CXCR6 led to a
better survival. Taking the hazard ratios of the individual
genes in multivariate analysis into account and to end up
with positive values only, a score ranging from 1 to 4 points
(pts) can be calculated as:
þ1 point; if the expression of CAP1 is > than the median
−1 point; if the expression of CXCR6 is > than the median
þ1 point; if the expression of FAM124B is > than the median
þ2 points in order to end up with positive values onlyð Þ
This score, named Tri-AML score (TriAS) highly pre-
dicted OS in the training set in multivariate Cox analysis
including age as a competing risk factor (p < 0.0001). To
further simplify, TriAS could also be categorized into
low-, intermediate-, and high-risk groups allowing reliable
segregation (1 pts: low risk, n = 31, 2/3 pts: intermediate
risk, n = 181, 4 pts: high risk n = 30, p < 0.0001, Fig. 2a).
TriAS remained independently significant in multivariate
Cox analysis including age in the NTUH validation set 1
(p < 0.0001) and showed a trend in the GSE12417-GPL96
validation set 2 (p = 0.1028). Kaplan-Meier plots are
shown in Fig. 2b, c).
TriAS predicts survival independently of established risk
factors
Current AML risk stratification is based on age and
cytogenetic risk group [16]. While the publicly available
patient data sets enrolled in the AMLCG-1999 trial only
included CN-AML patients with intermediate risk and
no further genetic discrimination, this information was
readily available in the TCGA and NTUH data sets as
previously described [9, 11].
In a direct multivariate analysis of both the TCGA
training and the NTUH validation set including cytogen-
etic risk group and age >65 years, TriAS remained inde-
pendently predictive for OS in both data sets (Table 1),
while clinical parameters were mainly similarly distrib-
uted within the different risk groups according to TriAS
(Additional file 1: Table S3).
In particular, since the older patients (age > 65 years)
remain a difficult-to-treat subpopulation, we then applied
TriAS to this age population using the combined four data
sets (n = 632). Even within the older patient cohort (n =
166), TriAS also allowed clear segregation of different risk
groups (median OS TriAS 1: 26.8 months, TriAS 2/3:
8.3 months, TriAS 4: 4.1 months; p < 0.0001).
Similarly, TriAS was also able to predict relapse-free
survival (RFS) in direct multivariate analysis including
age, gender, and molecular and cytogenetic risk factors,
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only available in the NTUH validation set 1 (p = 0.03;
Additional file 1: Table S4).
TriAS predicts independently of previously identified
gene expression scores
Recently, three highly predictive scoring models were
developed, such as a 7-gene score by Marcucci et al. [5]
and an 11-gene expression score both developed for
CN-AML patients proposed by Chuang et al. [11] or a
24-gene score by Li et al. [14] including several cytogeneti-
cally defined subsets. All three models were able to predict
survival in our applied data sets in univariate analysis
(data not shown). Notably, including cytogenetic risk,
gender, and age >65 as well as all four expression-based
risk scores into one multivariate Cox regression model,
only age >65 years and TriAS remained independently
predictive in the TCGA training set as well as the NTUH
validation set (Table 2).
Since all four scoring models have been developed in dif-
ferent training data sets, we then evaluated the prediction
ability in all data sets. While the score proposed by Li et al.
included patients with favorable and adverse cytogenetics,
both scores proposed by Chuang et al. and Marcucci et al.
were developed for CN-AML only. We nevertheless tested
their fitness in both the CN-AML and non-CN AML
subcohorts: Including age >65 and gender as competing
risk factors, only TriAS remained independently signifi-
cant in the CN patients of the TCGA training set, and
TriAS and the Chuang score remained significant in the
CN patients of the NTUH validation set 1 (Additional file
1: Table S5).
However, in the non-CN patients of the TCGA training
set, only TriAS remained significant, whereas in the sub-
cohort of non-CN patients of the NTUH validation set 1,
all four expression-based scoring models were able to
significantly predict survival independently of age >65,
gender, and the cytogenetic risk group (Additional file 1:
Table S6).
In order to test if expression-based scoring models could
be used synergistically, we sequentially combined TriAS
with each of the other three scores. Comparing “double low
risk” (TriAS = 1 and additional other low risk score),
“double high risk” (TriAS = 4 and additional other high risk
score), and “remaining” patients, each combination (TriAS/
a
p<0.0001
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Fig. 2 Categorized TriAS predicts overall survival of AML patients. Kaplan-Meier survival analysis of pooled patients from the TCGA data set and
enrolled into AMLCG-1999 (GSE12417-GPL570) (training set) (a) and two additional validation sets from either NTUH (b) or AMLCG-1999 (c) based
on TriAS categories are shown
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Marcucci, TriAS/Chuang, TriAS/Li) also allowed significant
segregation in both the training and validation set 1
(Additional file 1: Figure S2a-f). Moreover, comparison
of “quadruple low risk,” “quadruple high risk,” and
“remaining” patients utilizing all four scores also identified
subgroups with significant difference in OS (Additional
file 1: Figure S3a-c). But as expected, the addition of
several scores only partially improved the prognostic
segregation ability.
TriAS can further refine the European LeukemiaNet AML
classification
Current risk stratification of AML patients is mainly based
on the European LeukemiaNet (ELN) classification [17].
Patients are classified into four risk groups (favorable,
intermediate 1/2, and adverse) according to cytogenetics
and molecular profile based on mutational status of C/
EBPα, NPM1, and FLT3. Applying the ELN classification
in the combined data sets with cytogenetic and molecular
data allowed robust segregation of OS (Fig. 3a).
In each ELN risk group, high TriAS identified a substan-
tial number of patients with shorter survival allowing a
more refined definition of patient’s risk (Fig. 3b). Based on
median as well as 3-year OS, we developed a combined
ELN +TriAS risk stratification which allowed improved
risk segregation (Table 3; Fig. 3c). Overall, 167 (44.5 %) of
375 patients in our data sets with ELN risk available were
classified into a different risk category if TriAS was
included.
Discussion
In this study, we used genome-wide expression and clinical
data of multiple independent patient cohorts to propose a
simple three-gene expression-based scoring system named
TriAS. Although a variety of different risk factors have been
described in AML including patient-based factors, genetic
and epigenetic changes, and response to therapy [18], age
and karyotype remain the most important factors currently
used in clinical routine. TriAS showed to be a reliable inde-
pendent predictor of OS and RFS even in combination with
established risk factors and previously published scores in
our training sets as well in our validation sets.
The ELN recommendation is a commonly used risk
classification scheme for adult AML patients [17]. While
Table 1 Multivariate Cox regression analysis for OS including
age >65 years, cytogenetic and molecular risk factors, gender,
and TriAS in the TCGA training and all validation sets if available
are shown
HR multivariate p value
multivariate
TCGA training set (n = 154)
Cytogenetic risk group poor 1.505 (0.896–2.527) 0.1222
Cytogenetic risk group favorable 0.448 (0.228–0.881) 0.0200
FLT3 mutated 1.590 (0.946–2.672) 0.0799
NPM1 mutated 0.718 (0.419–1.229) 0.2267
Gender (female) 1.192 (0.790–1.797) 0.4033
Age > 65 4.472 (2.818–7.098) <0.0001
TriAS 1.978 (1.505–2.600) <0.0001
GPL570 training set (n = 79)
Age > 65 1.683 (0.943–3.007) 0.0784
TriAS 2.147 (1.557–2.961) <0.0001
NTUH validation set 1 (n = 221)
Cytogenetic risk group poor 2.504 (1.547–4.052) 0.0002
Cytogenetic risk group favorable 0.434 (0.234–0.802) 0.0077
CEBPA mutated 0.248 (0.098–0.629) 0.0033
FLT3 mutated 2.034 (1.320–3.135) 0.0013
NPM1 mutated 0.801 (0.483–1.328) 0.3893
Gender (female) 0.779 (0.526–1.152) 0.2109
Age > 65 2.064 (1.258–3.389) 0.0042
TriAS 1.393 (1.097–1.769) 0.0066
GPL96 validation set 2 (n = 163)
Age > 65 1.639 (1.097–2.449) 0.0159
TriAS 1.239 (1.014–1.515) 0.0361
italic p-values relate to significant findings (p<0.05)
Table 2 TriAS independently segregates survival of AML
patients even including other expression-based risk scores:
multivariate Cox regression analysis for OS of AML patients
from the TCGA training and the NTUH validation set 1 using
cytogenetic risk, gender, age >65 years, and TriAS as well as
scores developed by Marcucci, Chuang, and Li
HR multivariate p value
multivariate
TCGA training set (n = 161)
Cytogenetic risk group poor 1.516 (0.887–2.594) 0.1284
Cytogenetic risk group favorable 0.651 (0.329–1.290) 0.2186
Gender (female) 1.343 (0.894–2.018) 0.1557
Age > 65 3.817 (2.429–5.999) <0.0001
Marcucci score 1.090 (0.661–1.800) 0.7349
Chuang score 0.993 (0.949–1.039) 0.7603
Li score 1.432 (0.861–2.380) 0.1661
TriAS 2.148 (1.659–2.782) <0.0001
NTUH validation set (n = 221)
Cytogenetic risk group poor 2.229 (1.424–3.489) 0.0005
Cytogenetic risk group favorable 0.473 (0.256–0.873) 0.0167
Gender (female) 0.856 (0.583–1.257) 0.4283
Age > 65 2.252 (1.378–3.680) 0.0012
Marcucci score 0.952 (0.591–1.533) 0.8402
Chuang score 1.081 (1.040–1.124) <0.0001
Li score 1.126 (0.710–1.786) 0.6133
TriAS 1.337 (1.031–1.733) 0.0285
italic p-values relate to significant findings (p<0.05)
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ELN risk classification has substantially improved our
understanding how to identify high-risk patients with poor
overall survival, a subset of these patients is not properly
identified by this approach. Therefore, there have been
several approaches to further redefine patients at higher
risk. As such, a benchmark score proposed by Li et al.
similarly redefined poor (adverse) patients using their
24-gene score. This approach allowed to expand the iden-
tified high-risk cohort from 27 % (ELN alone) to 52 %
(ELN+ 24 gene score). Applying TriAS, we were able to
distinguish the individual patients’ risk in more detail.
Only 58.8 % of prior ELN favorable patients remained in
the favorable cohort when TriAS was applied. Subse-
quently, the ELN intermediate risk groups (1 and 2) can
be further segregated between a favorable, intermediate,
and adverse risk profile. In particular, within this group,
62.1 % were actually of adverse risk. This is also supported
by the findings by Li et al., who showed that a substantial
number of patients are of significant higher clinical risk
with a substantially shorter overall survival. Applying
TriAS could help to identify patients with ELN favorable
or intermediate prognosis who nonetheless may benefit
from intensified treatment regimens.
For prediction of OS in AML patients, several other
studies used a genome-wide approach. An 86-gene signa-
ture for CN-AML patients was described by Metzeler
et al., which despite its predictive value remains difficult
to implement due to the large gene number and has also
not been evaluated in non-CN AML subsets so far [4]. In
comparison, a more recent study used both genetic and
a
p<0.0001
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Fig. 3 TriAS refines the ELN classification to better segregate AML survival. Overall survival of the AML patients from the TCGA and NUTH data
sets according to current ELN classification is shown (a) or after implementation of the ELN and TriAS classification (ELN + TriAS) (c). The fraction
of patients reclassified based on original ELN and ELN + TriAS risk classification is shown (b)
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also epigenetic information to predict survival of AML.
While this elegant study by Marcucci et al. showed a highly
attractive approach to improve risk stratification, again this
study was only conducted in the CN-AML subset [5].
Additionally, an 11-gene score for CN-AML patients was
developed by Chuang et al. [11] and a 24-gene score by Li
et al. for both CN and non-CN AML patients. The score
developed by Li et al. allowed an excellent segregation also
in combination with established cytogenetic risk stratifi-
cation [14]. The combined use of the Li and TriAS score
led to a further discrimination of OS, notably using only
three additional genes. Moreover, the scores did not mark-
edly overlap as combining multiple expression-based risk
scores allowed further segregation of patient cohorts. This
supports the notion that several gene expression-based
prediction scores can be used synergistically and opens an
important novel avenue how scoring models could be
used in clinical application.
However, our calculations of multiple n-out-of-30 scores
clearly demonstrated that including a larger number of
genes into a scoring model holds an advantage for its
predictive value, but this improvement is saturated after a
limited number of genes. Since most algorithms include
the strongest predictors into a model first, the absolute
improvement naturally decreases with each additionally
predictor added. In our model, inclusion of more than
eight genes did not lead to any relevant further impro-
vement. However, weighing the number of genes to be
analyzed in clinical practice and the ability of prediction, a
3-gene-score remained most reasonable in this respect.
Functionally, the three most prognostic genes are only
partially described. CXCLR6 has shown to be the cognate
receptor of its natural ligand CXCL16 and was initially
described on peripheral blood leukocytes and to be present
in the bone marrow and prostate [19, 20]. CXCR6/CXCL16
has also been described as an oncogenic axis in a variety of
solid cancers, such as papillary thyroid carcinoma, gastric,
prostate, and breast cancer, through positive regulation of
survival pathways such as ERK [21–25]. Surprisingly, in our
data sets, a high expression of CXCR6 led to an improved
survival of AML patients. Therefore, subsequent functional
studies have to show if this axis might have cancer-type
specific functions suggesting to act either oncogenic or
tumor suppressive.
The second gene in our scoring model, FAM124B, has
just recently been identified, and its function remains to be
still fully understood. So far, FAM124B has been shown to
be an interaction partner for the chromodomain helicase
DNA binding protein 7 and 8 genes (CHD7 and CHD8).
Mutations of CHD7 are the major cause for the CHARGE
syndrome [26]. On note, it has to be mentioned that so far,
there are no studies showing a direct link between the
CHARGE syndrome and the onset of leukemia, except one
case study describing the co-existence of myelodysplastic
syndrome (MDS) [27] and the CHARGE syndrome in an
infant. For the interaction partner of FAM124B, CHD8,
one study so far described an oncogenic role in a mouse
model for BCR-ABL1+ acute lymphoblastic leukemia [28],
while neither the role of FAM124B nor its interaction with
CHD7/8 have been described so far in AML.
The third identified gene, CAP1, is an actin-regulating
protein which has been shown to promote tumor growth
and migration of solid cancers such as HCC, glioma, or
breast cancer [29–32]. These oncogenic functions are
mediated also by the ERK pathway as shown in breast
cancer cells [33]. While no direct oncogenic role for CAP1
was so far described in AML, one study [34] elucidated its
role as direct interacting partner for the insulin resistance
protein resistin which is secreted by monocytes [35].
Relevant to mention is that the model which was used to
study this interaction was based on the human monocytic
THP-1 cell line, which was derived from an AML patient
[36]. While these findings indicate a potential role for
CAP1 in AML, direct functional evidence so far is miss-
ing. In contrast to CXCR6, high expression of CAP1 and/
or FAM124B led to impaired overall survival in our data
sets in accordance to a suspected oncogenic role of these
two genes.
Conclusions
In summary, our 3-gene expression-based score TriAS
allowed robust prediction of AML survival independently
of previously identified risk factors with a reasonable low
number of genes to be analyzed in clinical practice. The
addition of TriAS to the current ELN risk classification
allowed a refined risk classification and might help to
identify patients who may benefit from intensified
Table 3 Combination of current ELN risk classification with
TriAS leads to a refined ELN + TriAS classification showing three
groups with adverse (≤25 %), intermediate (50–60 %), and
favorable (>60 %) survival after 3 years








Favorable 1 24 77.4 Not reached Favorable
Favorable 2 59 75.4 3555 Favorable
Intermediate 1/2 1 7 68.6 Not reached Favorable
Favorable 3 46 58.1 1805 Intermediate
Favorable 4 12 52.1 Not reached Intermediate
Intermediate 1/2 2 54 50.9 1193 Intermediate
Adverse 1 2 50.0 Not reached Intermediate
Intermediate 1/2 3 78 25.6 366 Adverse
Intermediate 1/2 4 22 23.9 214 Adverse
Adverse 2 24 21.4 368 Adverse
Adverse 3 30 18.2 347 Adverse
Adverse 4 17 0.0 214 Adverse
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treatment. However, future research is required to validate
the robustness of the score prospectively in clinical trials.
So far, all published scoring models including our own rely
on microarray data. With our simple 3-gene-score, future
routine clinical application may come within reach if our
results can be confirmed using harmonized quantitative
real-time PCR.
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based on incremental number of genes used. Figure S2. Combination of risk
scores improves the segregation of overall survival of AML patients. Figure S3.
Four risk scores can be used synergistically to segregate overall survival of
AML patients. (PDF 360 kb)
Acknowledgements
We thank the researchers of TCGA and of the AMLCG-1999 clinical trial for
making their expression and clinical patient data available, in particular
Klaus H. Metzeler.
Funding
This work is supported by grants from the Ernst Jung Foundation and
German Cancer Aid to BKM.
Availability of data and materials
The data sets supporting the conclusions of this article are included within
this article. The microarray data sets are available at the TCGA website or at
the GEO website (accession number GSE12417). The NTUH data sets can be
provided upon request to the authors.
Authors’ contributions
BKM and SW conceived and designed the study. BKM supported financially.
HFT provided the study materials or patients. BKM, SW, WCC, MKC, and HFT
contributed to the collection and assembly of data. SW and BKM analyzed
the data. SW, BKM, JP, EJ, WW, MC, and THB interpreted the data.
All authors wrote and approved the manuscript.
Competing interests
BKM receives research funding from Takeda & Novartis and honorary from
Janssen Pharmaceuticals which are not related to this study. The other
authors declare that they have no competing interests.
Consent for publication
Ethical approval by the individual IRBs is included in the original publications
[9–11].
Ethics approval and consent to participate
The study uses prior reported data sets [9–11]. Ethical approval by the
individual IRBs are included in the original publications [9–11].
Author details
1Department of Hematology, Oncology, Hemostaseology and Stem Cell
Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
2Department of Laboratory Medicine, National Taiwan University Hospital,
Taipei, Taiwan. 3Department of Internal Medicine, National Taiwan University
Hospital, Taipei, Taiwan. 4Helmholtz-Institute for Biomedical Engineering,
Stem Cell Biology and Cellular, Engineering, University Hospital of the RWTH
Aachen, Aachen, Germany. 5Institute for Biomedical Engineering - Cell
Biology, University Hospital of the RWTH, Aachen, Germany.
Received: 8 July 2016 Accepted: 24 August 2016
References
1. Bozic T, Lin Q, Frobel J, Wilop S, Hoffmann M, Muller-Tidow C, et al.
DNA-methylation in C1R is a prognostic biomarker for acute myeloid
leukemia. Clin Epigenetics. 2015;7:116. doi:10.1186/s13148-015-0153-6.
2. Jost E, Lin Q, Weidner CI, Wilop S, Hoffmann M, Walenda T, et al.
Epimutations mimic genomic mutations of DNMT3A in acute myeloid
leukemia. Leukemia. 2014;28(6):1227–34. doi:10.1038/leu.2013.362.
3. Chuang MK, Chiu YC, Chou WC, Hou HA, Chuang EY, Tien HF. A 3-
microRNA scoring system for prognostication in de novo acute myeloid
leukemia patients. Leukemia. 2015;29(5):1051–9. doi:10.1038/leu.2014.333.
4. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J,
Sauerland MC, et al. An 86-probe-set gene-expression signature predicts
survival in cytogenetically normal acute myeloid leukemia. Blood.
2008;112(10):4193–201. doi:10.1182/blood-2008-02-134411.
5. Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, et al.
Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel
seven-gene score. J Clin Oncol. 2014;32(6):548–56. doi:10.1200/JCO.2013.50.6337.
6. Pastore F, Dufour A, Benthaus T, Metzeler KH, Maharry KS, Schneider S, et al.
Combined molecular and clinical prognostic index for relapse and survival
in cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2014;32(15):
1586–94. doi:10.1200/JCO.2013.52.3480.
7. Zaidi SZ, Owaidah T, Al Sharif F, Ahmed SY, Chaudhri N, Aljurf M. The
challenge of risk stratification in acute myeloid leukemia with normal
karyotype. Hematol Oncol Stem Cell Ther. 2008;1(3):141–58.
8. Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF,
et al. Attempts to optimize induction and consolidation treatment in acute
myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010;28(4):
586–95. doi:10.1200/JCO.2009.22.9088.
9. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of
adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–74.
doi:10.1056/NEJMoa1301689.
10. Buchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, et al.
Double induction containing either two courses or one course of
high-dose cytarabine plus mitoxantrone and postremission therapy
by either autologous stem-cell transplantation or by prolonged
maintenance for acute myeloid leukemia. J Clin Oncol. 2006;24(16):2480–9.
doi:10.1200/JCO.2005.04.5013.
11. Chuang MK, Chiu YC, Chou WC, Hou HA, Tseng MH, Kuo YY, et al. An
mRNA expression signature for prognostication in de novo acute myeloid
leukemia patients with normal karyotype. Oncotarget. 2015;6(36):39098–110.
doi:10.18632/oncotarget.5390.
12. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al.
Cytoscape: a software environment for integrated models of
biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.
doi:10.1101/gr.1239303.
13. Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess
overrepresentation of gene ontology categories in biological networks.
Bioinformatics. 2005;21(16):3448–9. doi:10.1093/bioinformatics/bti551.
14. Li Z, Herold T, He C, Valk PJ, Chen P, Jurinovic V, et al. Identification of a
24-gene prognostic signature that improves the European LeukemiaNet
risk classification of acute myeloid leukemia: an international collaborative
study. J Clin Oncol. 2013;31(9):1172–81. doi:10.1200/JCO.2012.44.3184.
15. Shah A, Andersson TM, Rachet B, Bjorkholm M, Lambert PC. Survival and
cure of acute myeloid leukaemia in England, 1971-2006: a population-based
study. Br J Haematol. 2013;162(4):509–16. doi:10.1111/bjh.12425.
16. Estey EH. Acute myeloid leukemia: 2014 update on risk-stratification and
management. Am J Hematol. 2014;89(11):1063–81. doi:10.1002/ajh.23834.
17. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al.
Diagnosis and management of acute myeloid leukemia in adults:
recommendations from an international expert panel, on behalf
of the European LeukemiaNet. Blood. 2010;115(3):453–74.
doi:10.1182/blood-2009-07-235358.
18. Liersch R, Muller-Tidow C, Berdel WE, Krug U. Prognostic factors for acute
myeloid leukaemia in adults—biological significance and clinical use.
Br J Haematol. 2014;165(1):17–38. doi:10.1111/bjh.12750.
19. Deng HK, Unutmaz D, KewalRamani VN, Littman DR. Expression cloning of
new receptors used by simian and human immunodeficiency viruses.
Nature. 1997;388(6639):296–300. doi:10.1038/40894.
Wilop et al. Journal of Hematology & Oncology  (2016) 9:78 Page 9 of 10
20. Tabata S, Kadowaki N, Kitawaki T, Shimaoka T, Yonehara S, Yoshie O, et al.
Distribution and kinetics of SR-PSOX/CXCL16 and CXCR6 expression on
human dendritic cell subsets and CD4+ T cells. J Leukoc Biol. 2005;77(5):
777–86. doi:10.1189/jlb.1204733.
21. Cho SW, Kim YA, Sun HJ, Kim YA, Oh BC, Yi KH, et al. CXCL16 signaling
mediated macrophage effects on tumor invasion of papillary thyroid
carcinoma. Endocr Relat Cancer. 2016;23(2):113–24. doi:10.1530/ERC-15-0196.
22. Li Y, Fu LX, Zhu WL, Shi H, Chen LJ, Ye B. Blockade of CXCR6 reduces
invasive potential of gastric cancer cells through inhibition of AKT
signaling. Int J Immunopathol Pharmacol. 2015;28(2):194–200.
doi:10.1177/0394632015584502.
23. Richardsen E, Ness N, Melbo-Jorgensen C, Johannesen C, Grindstad T,
Nordbakken C, et al. The prognostic significance of CXCL16 and its
receptor C-X-C chemokine receptor 6 in prostate cancer. Am J Pathol.
2015;185(10):2722–30. doi:10.1016/j.ajpath.2015.06.013.
24. Singh R, Kapur N, Mir H, Singh N, Lillard Jr JW, Singh S. CXCR6-CXCL16 axis
promotes prostate cancer by mediating cytoskeleton rearrangement via
Ezrin activation and alphavbeta3 integrin clustering. Oncotarget. 2016.
doi:10.18632/oncotarget.6944.
25. Xiao G, Wang X, Wang J, Zu L, Cheng G, Hao M, et al. CXCL16/CXCR6
chemokine signaling mediates breast cancer progression by
pERK1/2-dependent mechanisms. Oncotarget. 2015;6(16):14165–78.
doi:10.18632/oncotarget.3690.
26. Batsukh T, Schulz Y, Wolf S, Rabe TI, Oellerich T, Urlaub H, et al.
Identification and characterization of FAM124B as a novel component
of a CHD7 and CHD8 containing complex. PLoS One. 2012;7(12):e52640.
doi:10.1371/journal.pone.0052640.
27. Prasad R, Basu B, Mishra OP, Singh UK, Singh MK. The co-existence of
CHARGE and myelodysplastic syndrome in a child. BMJ Case Rep.
2009;2009. doi:10.1136/bcr.05.2009.1859.
28. Shingleton JR, Hemann MT. The chromatin regulator CHD8 is a context-
dependent mediator of cell survival in murine hematopoietic malignancies.
PLoS One. 2015;10(11):e0143275. doi:10.1371/journal.pone.0143275.
29. Liu X, Yao N, Qian J, Huang H. High expression and prognostic role of CAP1
and CtBP2 in breast carcinoma: associated with E-cadherin and cell
proliferation. Med Oncol. 2014;31(3):878. doi:10.1007/s12032-014-0878-7.
30. Liu Y, Cui X, Hu B, Lu C, Huang X, Cai J, et al. Upregulated expression of CAP1
is associated with tumor migration and metastasis in hepatocellular carcinoma.
Pathol Res Pract. 2014;210(3):169–75. doi:10.1016/j.prp.2013.11.011.
31. Yu XF, Ni QC, Chen JP, Xu JF, Jiang Y, Yang SY, et al. Knocking down the
expression of adenylate cyclase-associated protein 1 inhibits the
proliferation and migration of breast cancer cells. Exp Mol Pathol.
2014;96(2):188–94. doi:10.1016/j.yexmp.2014.02.002.
32. Fan YC, Cui CC, Zhu YS, Zhang L, Shi M, Yu JS, et al. Overexpression of CAP1
and its significance in tumor cell proliferation, migration and invasion in
glioma. Oncol Rep. 2016. doi:10.3892/or.2016.4936.
33. Zhang H, Zhou GL. CAP1 (cyclase-associated protein 1) exerts distinct
functions in the proliferation and metastatic potential of breast cancer cells
mediated by ERK. Sci Rep. 2016;6:25933. doi:10.1038/srep25933.
34. Lee S, Lee HC, Kwon YW, Lee SE, Cho Y, Kim J, et al. Adenylyl cyclase-
associated protein 1 is a receptor for human resistin and mediates
inflammatory actions of human monocytes. Cell Metab. 2014;19(3):484–97.
doi:10.1016/j.cmet.2014.01.013.
35. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C,
et al. Resistin is expressed in human macrophages and directly regulated by
PPAR gamma activators. Biochem Biophys Res Commun. 2003;300(2):472–6.
36. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K.
Establishment and characterization of a human acute monocytic leukemia
cell line (THP-1). Int J Cancer. 1980;26(2):171–6.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wilop et al. Journal of Hematology & Oncology  (2016) 9:78 Page 10 of 10
